Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

40.0%

4 terminated/withdrawn out of 10 trials

Success Rate

55.6%

-30.9% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

80%

4 of 5 completed trials have results

Key Signals

1 recruiting4 with results

Enrollment Performance

Analytics

Phase 1

3(60.0%)

N/A

2(40.0%)

5Total

Phase 1(3)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT05124912Not ApplicableRecruiting

REMASTer: REcurrent Brain Metastases After SRS Trial

Role: lead

NCT02392078Completed

Laser Ablation of Abnormal Neurological Tissue Using Robotic NeuroBlate System

Role: lead

NCT05075850Completed

PatiEnt Neuropsychological outcomeS After laseR Ablation

Role: lead

NCT02820740Not ApplicableTerminated

Feasibility Study on LITT for Medical Refractory Epilepsy

Role: lead

NCT01651078Completed

Laser Ablation After Stereotactic Radiosurgery

Role: lead

NCT02389855Completed

Laser Ablation in Stereotactic Neurosurgery (LAISE): NeuroBlate® Retrospective Registry

Role: lead

NCT02880410Phase 1Terminated

Feasibility Study on LITT for Newly Diagnosed Glioblastoma

Role: lead

NCT04187872Phase 1Terminated

LITT and Pembrolizumab in Recurrent Brain Metastasis

Role: collaborator

NCT00747253Phase 1Completed

Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors

Role: lead

NCT03176160Withdrawn

LITT Palliative Treatment for Patients With Malignant Gliomas

Role: collaborator

All 10 trials loaded